These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35281930)

  • 1. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.
    Tang J; Ye L; Yan Q; Zhang X; Wang L
    Front Pharmacol; 2022; 13():800490. PubMed ID: 35281930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure.
    Packer M
    Cardiovasc Diabetol; 2023 Aug; 22(1):197. PubMed ID: 37533009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.
    Ansary TM; Nakano D; Nishiyama A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure.
    Kimura G
    Circ J; 2016 Oct; 80(11):2277-2281. PubMed ID: 27599528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection.
    Delanaye P; Scheen AJ
    Diabetes Metab; 2021 Nov; 47(6):101285. PubMed ID: 34597788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data.
    Rahhal A; Najim M; Abusweireh A; Habra M; Elgassim L; Ali MO; Habib MB; Tahtouh R; Al-Awad M; Aljundi AH; Mahfouz A; Ali MT; Dabdoob W; Alyafei S; Asaad N
    Curr Probl Cardiol; 2022 Oct; 47(10):100995. PubMed ID: 34571107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proximal versus distal diuretics in congestive heart failure.
    Nardone M; Sridhar VS; Yau K; Odutayo A; Cherney DZI
    Nephrol Dial Transplant; 2024 Feb; ():. PubMed ID: 38425090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.
    Vardeny O
    Am J Med; 2020 Feb; 133(2):182-185. PubMed ID: 31494110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis.
    Kimura G
    J Am Soc Hypertens; 2016 Mar; 10(3):271-8. PubMed ID: 26874564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.